Palisade Bio, Inc. (PALI) stock prices were down 3.4483% shortly after market trading commenced on July 29th, 2021, bringing the price per share down to USD$3.36 early on in the trading day.
Phase 2 LB1148 Trial
July 29th, 2021 saw the company announce the positive topline data from its Phase 2 clinical trial of LB1148. The treatment had a statistically significant effect in facilitating the acceleration of the restoration of bowel function in patients undergoing elective bowel resection surgery. The results indicate a strong efficacy profile in the acceleration of the time to recover bowel function. The treatment’s safety and tolerability profiles were also found to be favorable.
About LB1148
LB1148 is expected to simplify a patient’s surgery process, facilitating a faster recovery while potentially reducing costs to the healthcare system. The treatment has also been shown to statistically significantly accelerate the return of bowel function in a Phase 2 study for cardiovascular surgery, as well as a Phase 2 study for GI surgery. These data are the basis for the foundation of PALI stock proceeding to pivotal studies for these indications.
Scope of PALI Stock’s Treatment
The positive topline data brings PALI stock another step closer to commencing the launch of the first protease inhibitor indicated to accelerate the return of GI function. The typical delay of the return of bowel function affects millions of patients across the globe annually. Despite this, the treatment prospects for this global population has been relatively unchanged for decades. The treatment is forecasted to revolutionize the healthcare landscape for patients undergoing major surgery.
About the Clinical Trial
The Phase 2, multicenter, randomized, double-blind, parallel, placebo-controlled clinical trial was concluded as a critical part of a co-development agreement between PALI stock and Newsoara. The study included a total of 120 patients undergoing elective bowel resection surgery, covering both laparotomy and laparoscopic surgical approaches. Furthermore, the study also included patients undergoing either anastomosis or stoma creation. The primary endpoint of the study was the recovery of bowel function, which is measured as the time from the end of surgery to oral food tolerance and passage of stool.
Future Outlook for PALI Stock
Armed with the success of its positive topline data from its clinical study of LB1148, PALI stock is poised to capitalize on the range of opportunities afforded to it as a result. The company is keen to spearhead the continued development and eventual commercialization of its flagship treatment. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.
